Drugs / AT7519
AT7519
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02503709 | Sep 2016 → Aug 2020 | metastatic malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00390117 | Jan 2007 → Mar 2012 | cancer of unknown primary site, lymphoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01183949 | Nov 2010 → Dec 2014 | plasma cell myeloma | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01652144 | Sep 2012 → Dec 2014 | mantle cell lymphoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT01627054 | Aug 2012 → Mar 2014 | B-cell chronic lymphocytic leukemia | NCIC Clinical Trials Group | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT7519 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02503709 ↗ |
| Known as | AT7519M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01627054 ↗ |
| Known as | CDKI AT7519 | “Patients then receive onalespib IV over 1 hour and CDKI AT7519 IV over 1 hour on days 1, 4, 8, and 11 (cycle 1 and subsequent cycles thereafter).” NCT02503709 ↗ |
| Action | Inhibit | “AT7519 is a small-molecular inhibitor of multiple cyclin-dependent kinases (CDKs).” PMID 25393368 ↗ Nov 2014 |
| Modality | Small molecule | “AT7519 is a small-molecular inhibitor of multiple cyclin-dependent kinases (CDKs).” PMID 25393368 ↗ Nov 2014 |
| Route | Intravenous | “given as 1-h intravenous infusion on days 1, 4, 8 and 11 every 3 weeks.” PMID 25393368 ↗ Nov 2014 |